Foresite Capital Management IV, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Foresite Capital Management IV, LLC reported 6 stock positions worth $290.2 million. Its top holding was Pharvaris (PHVS) at 57.0% of the portfolio, followed by Cytokinetics (CYTK, 21.0%) and Eikon Therapeutics (EIKN, 8.7%). Compared with Q1 2026, it opened 1 new position, sold out of 3 and added to 2. The biggest buy was Cytokinetics (CYTK, shares +42%) and the biggest sale an exit from Lyell Immunopharma (LYEL).
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0001704132
- Portfolio Value
- $290.2M (Q2 2026)
- SEC Filing
- 0001104659-26-097103 ↗ filed Aug 14, 2026
Holdings Value
Holdings 6 stocks · $290.2M
| PHVS Pharvaris NV | 56.95% | 4,778,581 | $165.2M | No change |
| CYTK Cytokinetics Inc. | 20.98% | 714,695 | $60.9M | Add +42.0% |
| EIKN Eikon Therapeutics Inc. | 8.74% | 1,943,682 | $25.4M | No change |
| RLAY Relay Therapeutics Inc. | 8.06% | 1,250,000 | $23.4M | Add +25.0% |
| XENE Xenon Pharmaceuticals Inc. | 3.33% | 160,000 | $9.7M | No change |
| CRNX Crinetics Pharmaceuticals Inc. | 1.93% | 150,000 | $5.6M | New |
Portfolio Sells Q1 2026 → Q2 2026
Portfolio Buys Q1 2026 → Q2 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $290.2M | PHVS, CYTK, EIKN, RLAY, XENE |
| Q1 2026 | 8 | $237.1M | PHVS, CYTK, EIKN, LYEL, RLAY |
| Q4 2025 | 7 | $229.7M | PHVS, CYTK, LYEL, MAZE, RLAY |
| Q3 2025 | 6 | $182.6M | PHVS, CYTK, MAZE, LYEL, XENE |
| Q2 2025 | 6 | $123.8M | PHVS, MAZE, LYEL, XENE, KURA |
| Q1 2025 | 5 | $111.1M | PHVS, MAZE, LYEL, KURA, RLAY |
| Q4 2024 | 4 | $108.8M | PHVS, KURA, LYEL, RLAY |
| Q3 2024 | 5 | $153.0M | PHVS, KURA, SNDX, LYEL, RLAY |
| Q2 2024 | 4 | $148.8M | PHVS, KURA, SNDX, LYEL |
| Q1 2024 | 5 | $197.9M | PHVS, KURA, KNTE, SNDX, LYEL |